Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease. - Wikidata - wikimedia - TriplyDB

Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease.

Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease.

http://www.wikidata.org/entity/Q37803221

about

Impaired vascular-mediated clearance of brain amyloid beta in Alzheimer's disease: the role, regulation and restoration of LRP1 HDL and glucose metabolism: current evidence and therapeutic potential The development, past achievements, and future directions of brain PET Mild cognitive impairment: diagnosis, longitudinal course, and emerging treatments Mild mitochondrial metabolic deficits by α-ketoglutarate dehydrogenase inhibition cause prominent changes in intracellular autophagic signaling: Potential role in the pathobiology of Alzheimer's disease Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders Effects of emotionally charged auditory stimulation on gait performance in the elderly: a preliminary study.The link between cardiovascular risk, Alzheimer's disease, and mild cognitive impairment: support from recent functional neuroimaging studies.Age- and Brain Region-Specific Changes of Glucose Metabolic Disorder, Learning, and Memory Dysfunction in Early Alzheimer's Disease Assessed in APP/PS1 Transgenic Mice Using 18F-FDG-PET.Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment.Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia.Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia.Neuroplastic effects of combined computerized physical and cognitive training in elderly individuals at risk for dementia: an eLORETA controlled study on resting states.Brain Metabolism of Less-Educated Patients With Alzheimer Dementia Studied by Positron Emission Tomography.Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease.Expression of Tau protein in rats with cognitive dysfunction induced by cerebral hypoperfusion White Matter Lipids as a Ketogenic Fuel Supply in Aging Female Brain: Implications for Alzheimer's Disease.Noninvasive brain stimulation in Alzheimer's disease: systematic review and perspectives for the future.Effects of hypertension and diabetes on sentence comprehension in aging Functional neuroimaging using F-18 FDG PET/CT in amnestic mild cognitive impairment: A preliminary study Glucose metabolism in normal aging and Alzheimer's disease: Methodological and physiological considerations for PET studies.Multicenter stability of resting state fMRI in the detection of Alzheimer's disease and amnestic MCI.From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution.Mild cognitive impairment: a concept in evolution Perfusion SPECT and FDG-PET.Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment.Quintessential risk factors: their role in promoting cognitive dysfunction and Alzheimer's disease.Death by a thousand cuts in Alzheimer's disease: hypoxia--the prodrome.What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 2: chronic progressive and relapsing disease.Cell-specific blood-brain barrier regulation in health and disease: a focus on hypoxia.Regional neuronal network failure and cognition in late-onset sporadic Alzheimer disease.[Vascular factors in the pathogenesis of Alzheimer's disease].Evidence for brain glucose dysregulation in Alzheimer's disease.Decreased hippocampal metabolism in high-amyloid mild cognitive impairment.Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.Treatment of Mild Cognitive Impairment.Lipopolysaccharide Associates with Amyloid Plaques, Neurons and Oligodendrocytes in Alzheimer's Disease Brain: A Review.Computer-aided diagnostic reporting of FDG PET for the diagnosis of Alzheimer’s disease

P2860

Q26800063-C12777D7-DC8D-4C72-9710-44F609E6A26B Q26996502-FC700AF3-B551-40B2-8830-8E718C51B087 Q27026331-517244E6-7933-44C6-BF17-7487A93B77C0 Q27026362-E61C969D-E59D-4D78-AF25-DBC2FCAE0BE0 Q28393932-3333F85A-BEF0-4EBC-BDEB-C00DA10E5CBC Q29615839-C0F975F7-76C1-49CF-82C1-3DCC1A0A9697 Q30386903-0CDB908A-1127-46CB-BEC9-8B797A8A8B96 Q30830414-199D9959-DE0A-4999-8B5F-5B2C5D747BD3 Q31138018-D6978E81-8103-41C0-AF72-54FC9CD49629 Q34462406-AA55FAE1-6AEA-4880-9273-A92DCCC96002 Q34477727-39C5288B-BF94-4144-B761-EF54332B3809 Q34988649-E70A0318-AD5D-41DC-8FB3-98A1E3567280 Q35117821-A1D78247-D025-4FDA-A0B5-466955EF8CF2 Q35512038-1B8784B7-82D9-4B88-A6A7-70B5CD0E6A35 Q36009364-C7B62259-E902-4FA1-BDCD-27BB0BCEC324 Q36018654-A58501F3-BA41-45AC-AF5B-44F65D27D8B2 Q36330297-A125AE43-A178-4F00-9247-26997BC7E415 Q36412428-6BCD4915-9E1E-4CC0-B618-9751D6BE058A Q36437623-4A20BBCF-B813-498E-BAAE-1AD17B685245 Q36661005-D4351F6F-ABF2-4D72-8ED5-D6786C860300 Q36908006-5464C411-031E-4E00-9808-6CE9C20CAF80 Q37293609-AE0BDEB4-55FE-4405-A2E8-89AE4D2B6EB4 Q37436607-9D607DC4-1235-483D-B0EA-AC966A85D0DB Q37613576-2D1E0937-F4C3-44CD-8991-4A060E30AB9F Q37653048-283C50D4-4D5D-4E9B-B698-17B047FB9B10 Q37668090-2F6B7D7A-CE31-43B7-B86A-C65AFF753E44 Q37897692-B72B43E1-AB29-4729-B369-15AD60D08C6B Q37976853-1F9CCC35-3F5F-48C7-8239-4D134BD5BB6E Q38034108-357B32CC-628F-46DD-AA04-6ABB3E477E5A Q38080761-8DD416A2-9300-4B78-BEE1-2E379C1BD961 Q38088747-CD2DFC67-8DE6-4877-8C13-318328B5B6EB Q38196884-762932DA-3F3F-4604-8EA7-88143CE263FE Q38435318-A9E664A1-E2BF-4058-B0C0-ADE1D2D9576F Q45955749-B91A4C02-B583-4096-83C4-9416728FFD2A Q47620628-A573CA3B-37D4-4D53-9A69-02C6EF2C6BE1 Q48621788-A0AE342B-17C5-44B2-953C-B0C93A601A68 Q48715994-EDD47D53-5A3A-498D-BA0D-65B98BE936C0 Q50720439-55B48993-BBD5-4653-801D-C447544B2EC5 Q51764702-41B2D168-EB5D-49CE-B947-A75A23C096A2 Q57741276-AF10EBF1-B1BF-41AA-BF17-FAE85E4272C6

P2860

Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease.

http://www.wikidata.org/entity/Q37803221

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease.

@en

Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease.

@nl

type

label

Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease.

@en

Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease.

@nl

prefLabel

Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease.

@en

Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease.

@nl

P1433

Q37803221-7BAC5B38-1EBC-443C-BFA1-E5EAF04AD895

P1476

Q37803221-5BE1F698-C721-4C53-A3C4-590483DBDB3B

P2093

Q37803221-90916659-AEFE-4D3F-9F53-FF9EFBCAB0D8

P2860

Q37803221-02662756-66A8-4990-951F-5E4EF07ADDA5

Q37803221-050D8565-E66F-4D90-84A7-5527ED9C982B

Q37803221-07052A5B-2BBE-4BC2-9E08-C6856F0D6122

Q37803221-081E2616-D543-4CF3-9DEA-3FAC5D53FCF8

Q37803221-0EFCC82A-CE23-4B8C-A54D-4C5ED2A39CC2

Q37803221-14870EA7-5D21-44EC-82E7-B4D68DD6EDBE

Q37803221-192A2385-A36D-45D1-931F-E366BA29822F

Q37803221-1CB120AA-67AA-4B29-AF64-8C4A342DDD64

Q37803221-1FCF6E64-2970-4CD7-8AFA-0F8A12CCD2B8

Q37803221-23AE2B1F-0220-412C-BD90-53698E9B1B26

P304

Q37803221-2AC9A958-7F03-4ABB-8F6D-B430F6C3AB84

P31

Q37803221-1C3DF15B-9246-41DA-A2A1-CD726097B0E2

P356

Q37803221-31E0C12E-3938-4ABC-BB55-C3B6D25ED637

P433

Q37803221-1C4145F0-0C5A-4C75-A44E-DBCEC37F51FC

P478

Q37803221-FD98A114-B11B-4766-8395-8E559E3A0387

P577

Q37803221-6F34C9D8-B797-400A-82FB-C496111C4902

P698

Q37803221-BDC4E9F2-D64B-49C4-A6A8-53CB242987ED

P921

Q37803221-0E4EAACF-DEE1-42C3-9143-2F2BE3DE2CBF

Q37803221-C84BFAA1-528C-48DB-A71B-E201124B5439

P356

P1433

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

P1476

Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease.

@en

P2093

Karl Herholz

http://www.w3.org/2001/XMLSchema#string

P2860

Statistical parametric maps in functional imaging: A general linear approach

Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve.

Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative

Comparison of 18F-FDG and PiB PET in cognitive impairment.

Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET).

Integrating ADNI results into Alzheimer's disease drug development programs.

Comparing predictors of conversion and decline in mild cognitive impairment.

P304

1667-1673

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERN.10.136

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20977325

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease